Weapons technology repurposed

-A A +A

Nanotitanium is the product of a collaboration between LANL and Russian scientists

By The Staff

A group of ground-breaking American and Russian scientists, led by Dr. Terry Lowe, chief scientist at Manhattan Scientifics (MHTX) are taking Cold War weapons technology and repurposing it for peaceful use in medical prosthetics and dental implants.
Manhattan Scientifics holds exclusive licensed U.S. rights from Los Alamos National Laboratory.
Nanotitanium, a new FDA-approved super-
metal that is stronger than conventional metal alloys, integrates more quickly with human bone — and is expected to be more reliable, longer lasting and provide faster post-surgery healing.
Nanotitanium is the product of a collaboration of U.S. scientists at LANL and Russian weapons technology scientists who teamed together under direction from the U.S. Global Initiative for Proliferation Prevention at the U.S. Dept. of Energy.
On Thursday, the first FDA-approved dental implant made with nanotitanium was installed in Dr. Terry Lowe’s mouth, the scientist who helped develop it.
The dental procedure was followed by a press conference Friday to announce the official start of the production and sales of nanostructured titanium.
The dental implant is manufactured and distributed by Basic Dental Inc. of Albuquerque, under a limited license from Manhattan Scientifics, who also issued a broader exclusive license to a major Fortune 1000 U.S. NYSE metals manufacturing company to cover other medical and non-medical applications for the new class of super strong, super light metals.
“The dental implant market is characterized as a large under-penetrated global opportunity. In the recent years, increasing aging population coupled with rising awareness for oral health, high esthetics and improved dental treatments have boosted the growth of this segment to double digits thanks to the rising edentulous population worldwide,” said CEO Manny Tsoupanarias.
Marvin Maslow, Manhattan Scientific founder and director of public relations and investor
relations said, “We’re living longer and we need new parts,” Manhattan Scientifics is in the new parts business and it is a big business.
The current worldwide dental implant market is $3.5 billion this year, according to a study prepared by Kalorama Information. The potential for our new product beyond the dental market is significant.
‘Dental’ application is only the tip of the iceberg. The global market for minimally invasive prosthetic devices is presently at $23 billion. Our goal by introducing Nanotitanium is to trigger the beginning of a new era for the prosthetics and medical device industry.”
U.S. Sen. Tom Udall, D-N.M., said that it goes without saying that the product of this unique collaboration between American and Russian scientists at LANL is an important innovation for medicine.
“Three decades ago, this kind of partnership would have been unimaginable, but today these scientists have utilized technology originally developed for nuclear weapons for peaceful means,” Udall said. “These are exactly the kind of partnerships we should be doing more of in New Mexico.”
Tsoupanarias added, “We are already cash-flow-positive thanks to our budding relationship with our top-class industrial manufacturing partner. Our business plan to focus on the nano-medicine space is expected to create significant earnings for us in the near term.”
Udall symbolically started the manufacturing process with a mouse click in the lab Friday.  
The National Nuclear Security Administration (NNSA) Friday highlighted the launch of the latest commercial product successfully developed and brought to market as a result of the Global Initiatives for Proliferation Prevention (GIPP) program.
NNSA’s GIPP program helps advance global nonproliferation efforts through collaborative research and development that applies the expertise of former weapons of mass destruction personnel to the development of civil-use technologies.
Created under a three-year partnership between LANL, several Russian institutes and New Mexico-based Manhattan Scientifics, the new implant material is more reliable and longer lasting and should result in faster post-surgery healing. It is the first dental implant made with nanotitanium that has been approved by the Food and Drug Administration.
“NNSA’s GIPP program prevents the spread of nuclear materials, technology and expertise by promoting cutting-edge science and technology built using the expertise of former weapons experts,” said NNSA Principal Assistant Deputy Administrator for Defense Nuclear Nonproliferation Ken Baker. “The program generates peaceful and commercially viable projects while achieving a critical nonproliferation goal.”
To date, the GIPP program has engaged more than 17,000 experts (at least 60 percent with experience working with weapons of mass destruction) from more than 180 facilities in the former Soviet Union, Libya and Iraq.
Since 1994, GIPP has partnered with more than 160 U.S. companies, multinational corporations and small innovative businesses to promote high-tech commercial research and development projects.
Under the program, partners provide financial or in-kind contributions equal in value to the funds NNSA commits to each project.
Partnering with U.S. companies increases the likelihood that projects will have attainable and sustainable commercial goals.  
Located in New Mexico, New York and Montreal, Manhattan Scientifics owns the exclusive, U.S. license to a family of patents, which will enable the manufacture and marketing of super strong, ultra light-weight “nanostructured” metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union.
More information about Manhattan Scientifics can be found at www.mhtx.com.